Quidel Posts 36 Percent Drop in Q1 Revenues on Weak Flu Season | GenomeWeb

NEW YORK (GenomeWeb News) – Quidel reported after the close of the market Wednesday that its first-quarter revenues fell 36 percent as a weak cold and flu season hit the firm's sales.

The San Diego-based diagnostics company reported total revenues of $38 million for the three-month period ended March 31, compared to $59.6 million for the first quarter of 2011. It fell short of Wall Street's consensus estimate of $40.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.